<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Vestnik dermatologii i venerologii</journal-id><journal-title-group><journal-title xml:lang="en">Vestnik dermatologii i venerologii</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник дерматологии и венерологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0042-4609</issn><issn publication-format="electronic">2313-6294</issn><publisher><publisher-name xml:lang="en">Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1031</article-id><article-id pub-id-type="doi">10.25208/vdv1031</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Pro-inflammatory IL-1 and TNF alpha cytokines in affected skin foci in psoriatic patients</article-title><trans-title-group xml:lang="ru"><trans-title>Провоспалительные цитокины ИЛ-1 и ФНО-α в очагах пораженнойкожи больных псориазом</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Katunina</surname><given-names>O R</given-names></name><name xml:lang="ru"><surname>Катунина</surname><given-names>О Р</given-names></name></name-alternatives><bio xml:lang="ru"><p>заведующая лабораторией патоморфологиик.м.н; ФГУ «ГНЦДК»Минздравсоцразвития России</p></bio><email>katunina@cnikvi.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rezaykina</surname><given-names>A V</given-names></name><name xml:lang="ru"><surname>Резайкина</surname><given-names>А В</given-names></name></name-alternatives><bio xml:lang="ru"><p>ведущий научный сотрудник отделения клинической иммунологиид.м.н; ФГУ «ГНЦДК» Минздравсоцразвития России</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Katunina</surname><given-names>O R</given-names></name><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name><surname>Rezaikina</surname><given-names>A V</given-names></name><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ФГУ «ГНЦДК»Минздравсоцразвития России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ФГУ «ГНЦДК» Минздравсоцразвития России</institution></aff></aff-alternatives><aff id="aff3"><institution></institution></aff><pub-date date-type="pub" iso-8601-date="2011-08-15" publication-format="electronic"><day>15</day><month>08</month><year>2011</year></pub-date><volume>87</volume><issue>4</issue><issue-title xml:lang="en">NO4 (2011)</issue-title><issue-title xml:lang="ru">№4 (2011)</issue-title><fpage>25</fpage><lpage>30</lpage><history><date date-type="received" iso-8601-date="2020-03-11"><day>11</day><month>03</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2011, Katunina O.R., Rezaykina A.V., Katunina O.R., Rezaikina A.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2011, Катунина О.Р., Резайкина А.В., Katunina O.R., Rezaikina A.V.</copyright-statement><copyright-year>2011</copyright-year><copyright-holder xml:lang="en">Katunina O.R., Rezaykina A.V., Katunina O.R., Rezaikina A.V.</copyright-holder><copyright-holder xml:lang="ru">Катунина О.Р., Резайкина А.В., Katunina O.R., Rezaikina A.V.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnikdv.ru/jour/article/view/1031">https://vestnikdv.ru/jour/article/view/1031</self-uri><abstract xml:lang="en"><p>The article presents the authors data related to an ongoing study of the expression of pro-inflammatory IL-1 and TNF
alpha cytokines in affected skin foci in psoriatic patients. The authors revealed particular features related to the increased
expression of IL-1 in the skin structures with absence of TNF alpha expression.</p></abstract><trans-abstract xml:lang="ru"><p>Приведены собственные данные по одновременному исследованию экспрессии провоспалительных цитокинов
ИЛ-1 и ФНО-α в пораженной коже больных псориазом. Выявленные особенности заключаются в повышении
экспрессии ИЛ-1 на структурах кожи при отсутствии экспрессии ФНО-α.</p></trans-abstract><kwd-group xml:lang="en"><kwd>psoriasis</kwd><kwd>interleukin-1</kwd><kwd>tumor necrosis factor alpha</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>псориаз</kwd><kwd>интерлейкин-1</kwd><kwd>фактор некроза опухоли-альфа</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Traub M., Marshall K.M.S. Psoriasis - Pathophysiology, Conventional, and Alternative Approaches to Treatment. Alternative Med Rev 2007; 12: 4: 319-330.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Sabat R ., Philipp S., Höflich C . et al. Immunopathogenesis of psoriasis. Exp Dermatology 2007; 157: 165-167.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Nickoloff B.J., Nestle F.O. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004; 113: 12: 1664-1675.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Воспаление. Руководство для врачей/ Под ред. В.В. Серова, В.С. Паукова. М.: Медицина, 1995; 640.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Симбирцев А.С. Новые возможности применения цитокинов в дерматологии и косметологии. Вестн. эстет. мед. 2010; 9: 2: 44-50.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Oppenheim J., Feldman M. (Eds) Cytokine Reference. London: Academic Press, 2000; 2015.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Кетлинский С.А., Симбирцев А.С. Цитокины. СПб.: Фолиант 2008; 552.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Симбирцев А.С. Цитокиныновая система регуляции защитных реакций организма. Цитокины и воспаление 2002; 1: 1: 9-16.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Телетаева Г.М. Цитокины и противоопухолевый иммунитет. Практ. онкол. 2007; 8: 4: 211-218.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Бережная Н.М. Цитокиновая регуляция при патологии: стремительное развитие и неизбежные вопросы. Цитокины и воспаление 2007; 2: 26-34.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Симбирцев А.С. Интерлейкин-1. Биологические свойства и перспективы применения в клинике. Вестн. оторин. 1997; 4: 10-16.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Schoch P., Помыткин И. Интерлейкин-1- альфа - эпидермальный цитокин, регулятор процессов формирования и функционирования кожи (обзор). Эстет. мед. 2010; IX: 2: 115-122.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Szabowski A., Maas-Szabowski N., Andrecht S. et al. C-Jun and Jun-B antagonistically control cytokine-regulated mesenchymal-epidermal interaction in skin. Cell 2000; 103: 5: 745-755.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Maas-Szabowski N., Stark H.J., Fusenig N.E. Keratinocyte growth regulation in defined organotypic cultures through IL-1-induced keratinocyte growth factor expression in resting fibroblasts. J Invest Dermatol 2000; 114: 6: 1075-1084.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Mauviel A., Heino J., Kähäri V.M. et al. Comparative effects of interleukin-1 and tumor necrosis factor -alpha on collagen production and corresponding procollagen mRNA levels in human dermal fibroblasts. J Invest Dermatol 1991; 96: 2: 243-249.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Swope V.B., Abdel-Malek Z., Kassem L.M. et al. Interleukins 1 alpha and 6 and tumor necrosis factor-alpha are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J Invest Dermatol 1991; 96: 2: 180-185.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Ярилин А.А. Основы иммунологии. М.: Медицина 1999; 606.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Cooper K., Hammerberg C., Baadsgaard O. et al. IL-1 activity is reduced in psoriatic skin: decreased IL-1 alpha and increased non-functional IL-beta. J Immunol 1990; 144: 4593-4403.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Debets R., Hegmans J.P., Troost R.J. et al. Enchanced production of biologically active interleukin-1α and interleukin-1βby psoriatic epidermal cells ex vivo: evidence of increased cytosolic interleukin-1β levels and facilitated interleukin-1 release. J Immunol 1995; 25: 6: 1624-1630.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Громова А.Ю., Чаплыгин А.В., Самцов А.В. и др. Различие показателей воспалительного ответа в коже при распространенном вульгар- ном псориазе и псориатическом артрите. Росс. журн. кожн. и венер. бол. 2005; 5: 23-27.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Kunkel S.L., Remick D.G., Strieter R.M. et al. Mechanisms that regulate the production and effects of tumor necrosis factor-α. Crit Rev Immunol 1989; 9: 93-117.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Соколов Д.И., Кузнецова С.А., Котов А.Ю. и др. Цитокиновая регуляция экспрессии адгезионных молекул ICAM-1 и продукции хемокина IL-8 эндотелиальными клетками. Мед. иммунол. 2000; 2: 1: 25-33.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Goldring S.R. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Reumatology 2003; 42(2):ii11-16.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Белова О.В., Арион В.Я., Сергиенко В.И. Роль цитокинов в иммунологической функции кожи. Иммунопатология, аллергология, инфектология 2008; 1: 41-55.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Ettenhadi P., Greaves M.W., Wallach D. et al. Elevated tumor necrosis factor-α (TNF-α) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96: 146-151.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Nickolof B.J. Karabin G.D., Barker J.N. et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Patho. 1991; 138: 129-40.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Mussi A., Bonifati C., Carducci M. et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 1997; 11: 115-118.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Маркушева Л.И., Самсонов В.А., Саруханова А.Г. и др. Оценка продукции различных цитокинов у больных псориазом. Вестн. дерматол. и венерол. 2004; 4: 4-6.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Patsch G., Steiner G., Leeb B.F. et al. Highly increased levels of tumor necrosis factor α and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24: 518-523.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Krueger G., Callis K. Potential of tumor necrosis factor inhibitors in psoriasic and psoriatic arthritis. Arch Dermatol 2004; 140: 218-225.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Ковальчук Л.В., Ганковская Л.В., Хорева М.В., Соколов Е.В. Система цитокинов, комплемента и современные методы им- мунного анализа. М.; 2001; 165.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Хаитов Р.М., Игнатьева Г.А., Сидорович И.Г. Иммунология. Норма и патология: Учебник.- 3-е изд. перераб. и доп. М.: Медицина 2010; 752.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Pomytkin I. Interleukin-1 alpha, an epidermal cytokine critical for skin reneval. SDFW-Journal 2009; 135; 8: 2-6.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Gahring L.C., Buckley A., Daynes R.A. Presence of epidermal-derived thymocyte activating factor/interleukin 1 in normal human stratum corneum. J Clin Invest 1985; 76; 4: 1585-9.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>De Jongh C.M., Verberk M.M., Spiekstra S.W. et al. Cytokines at different stratum corneum levels in normal and sodium lauryl sulphateirritated skin. Skin Res and Technol, 2007; 13: 390-398.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Schmitt A., Hauser C., Jaunin F. et al. Normal epidermis contains high amounts of natural tissue IL 1 biochemical analysis by HPLC identifies a MW approximately 17 Kd form with a P1 5.7 and a MW approximately 30 Kd form. Lymphokine Res 1986;5; 2: 105-18.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Barker B., Fry L. The immunology of psoriasis. Br J Dermatol 1991; 27; 338: 227-230.</mixed-citation></ref></ref-list></back></article>
